Traitement percutane des communications inter-auriculaires et des foramen ovales permeables.

LEMPEREUR, Mathieu; Lancellotti, Patrizio

Download

Article (Scientific journals)

Traitement percutane des communications inter-auriculaires et des foramen ovales permeables.

LEMPEREUR, Mathieu; Lancellotti, Patrizio

2019 • In Revue Médicale de Liège, 74 (S1), p. 87-S96

Peer reviewed

Permalink
https://hdl.handle.net/2268/238988

PubMed
31070322

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2019S1_15.pdf

Publisher postprint (600.23 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Atrial septal defect; Patent foramen ovale; Structural heart disease; Percutaneous cardiac intervention

Abstract :

[en] Atria septal defect (ASD) is one of the most common congenital heart disease. ASD can be responsible for a volume overload of the right chambers associated with an increased morbi-mortality. In these circumstances, percutaneous closure of ASD secundum-type is recommended as a first line therapy. The persistence of a patent foramen ovale (PFO) is found in approximately 25 % of adults. This anomaly can be responsible for paradoxical embolism, especially cryptogenic stroke. Recent studies have shown a clinical benefit to the percutaneous closure of FOP in cryptogenic stroke, with a modest, but significant, decrease in the risk of recurrence. In this article, we discuss the indications and procedure for percutaneous closure of ASD and PFO.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

LEMPEREUR, Mathieu ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Cardiologie interventionnelle

Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation

Language :

French

Title :

Traitement percutane des communications inter-auriculaires et des foramen ovales permeables.

Alternative titles :

[en] Percutaneous treatment of atrial septal defect and patent foramen ovale

Publication date :

2019

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

S87-S96

Peer reviewed :

Peer reviewed

Available on ORBi :

since 28 August 2019

Statistics

Number of views

157 (4 by ULiège)

Number of downloads

1406 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Tobis J, Shenoda M.- Percutaneous treatment of patent foramen ovale and atrial septal defects. J Am Coll Cardiol, 2012, 60, 1722-1732.
Baumgartner H, Bonhoeffer P, De Groot NMS, et al.- ESC Guidelines for the management of grown-up congenital heart disease. Eur Heart J, 2010, 31, 2915-2957.
Warnes CA, Williams RG, Bashore TM, et al.-ACC/AHA 2008 Guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol, 2008, 52, 1890-1947.
Hagen PT, Scholz DG, Edwards WD.- Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc, 1984, 59, 17-20.
Meissner I, Whisnant JP, Khandheria BK, et al.-Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: The SPARC study. Mayo Clin Proc, 1999, 74, 862-869.
Allemann Y, Hutter D, Lipp E, et al.- Patent foramen ovale and high-altitude pulmonary edema. JAMA , 2006, 296, 2954-2958.
Shanoudy H, Soliman A, Raggi P, et al.- Prevalence of patent foramen ovale and its contribution to hypoxemia in patients with obstructive sleep apnea. Chest, 1998, 113, 91-96.
Colombo B, Libera DD, Comi G.- Brain white matter lesions in migraine: What's the meaning? Neurol Sci, 2011, 32, 37-40.
Pinto FJ.- When and how to diagnose patent foramen ovale. Heart, 2005, 91, 438-440.
Adams HP, Bendixen BH, Kappelle LJ, et al.-Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 1993, 24, 35-41.
Fonseca AC FJ.- Cryptogenic stroke. New Engl J Med, 2015, 22, 618-623.
Lamy C, Giannesini C, Zuber M, et al.- Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA study. Stroke, 2002, 33, 706-711.
Homma S.- Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation, 2002, 105, 2625-2631.
Lee PH, Song J-K, Kim JS, et al.- Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol, 2018, 71, 2335-2342.
Kent DM, Thaler DE.- The Risk of Paradoxical Embolism (RoPE) Study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke. Trials, 2011, 12, 1-9.
Prefasi D, Martínez-Sánchez P, Fuentes B, et al.-The utility of the RoPE score in cryptogenic stroke patients ≤50 years in predicting a stroke-related patent foramen ovale. Int J Stroke, 2016, 11, NP7-NP8.
Pristipino C, Sievert H, D'Ascenzo F, et al.- European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J, 2018, in press.
Saver JL, Carroll JD, Thaler DE, et al.- Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med, 2017, 377, 1022-1032.
Søndergaard L, Kasner SE, Rhodes JF, et al.-Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med, 2017, 377, 1033-1042.
Mas J-L, Derumeaux G, Guillon B, et al.- Patent foramen ovale closure or anticoagulation vs. anti-platelets after stroke. N Engl J Med, 2017, 377, 1011-1021.
Mojadidi MK, Elgendy AY, Elgendy IY, et al.-Transcatheter patent foramen ovale closure after cryptogenic stroke. JACC Cardiovasc Interv, 2017, 10, 2228-2230.
Giacoppo D, Caronna N, Frangieh AH, et al.-Long-term effectiveness and safety of transcatheter closure of patent foramen ovale compared with antithrombotic therapy alone: A meta-analysis of six randomised clinical trials and 3,560 patients with reconstructed time-to-event data. EuroIntervention, 2018, 14, 857-867.
Stortecky S, Cook S, Meier B, et al.- Patent foramen ovale: A culpable pathway for myocardial infarction. J Am Coll Cardiol, 2011, 58, 1923-1928.
Cartoni D, De Castro S, Valente G, et al.- Identification of professional scuba divers with patent foramen ovale at risk for decompression illness. Am J Cardiol, 2004, 94, 270-273.
Torti SR, Billinger M, Schwerzmann M, et al.- Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J, 2004, 25, 1014-1020.
Pearman A, Bugeja L, Nelson M, et al.- An audit of persistent foramen ovale closure in 105 divers. Diving Hyperb Med, 2015, 45, 94-97.
Canivet A, Lancellotti P.- Syndrome de platypnée-orthodéoxie: une observation clinique perspicace. Rev Med Liege, 2017, 72, 494-498.
Cheng TO.- Platypnea-orthodeoxia syndrome: Etiology, differential diagnosis, and management. Catheter Cardiovasc Interv, 1999, 47, 64-66.
Delgado G, Inglessis I, Martin-Herrero F, et al.-Management of platypnea-orthodeoxia syndrome by transcatheter closure of atrial communication: hemodynamic characteristics, clinical and echocardiographic outcome. J Invasive Cardiol, 2004, 16, 578-582.
Irwin B, Ray S.- Patent foramen ovale assessment and treatment. Cardiovasc Ther, 2012, 30, e128-135.
Lip PZY, Lip GYH.- Patent foramen ovale and migraine attacks: a systematic review. Am J Med, 2014, 127, 411-420.
Rundek T, Elkind MS V, Di Tullio MR, et al.-Patent foramen ovale and migraine: A cross-sectional study from the Northern Manhattan Study (NOMAS). Circulation, 2008, 118, 1419-1424.
Meier B, Lock JE.- Contemporary management of patent foramen ovale. Circulation, 2003, 107, 5-9.
Dowson A, Mullen MJ, Peatfield R, et al.- Migraine intervention with STARFlex technology (MIST) trial: A prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation, 2008, 117, 1397-1404.
Mattle HP, Evers S, Hildick-Smith D, et al.- Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J, 2016, 37, 2029-2036.